Aikemai is an innovative technology platform in the field of cardiac electrophysiology. It independently develops pulsed electric field ablation technology (PFA). Taking atrial fibrillation ablation as the entry point, it takes the lead in developing the main engine and ablation catheter, and further deploys a three-dimensional mapping and navigation system and new supporting tools. In the future, it will expand to tumor ablation therapy, and create an integrated solution for the research and development of pulse ablation active equipment and supporting consumables for atrial fibrillation and tumors. Recently, nearly 100 million yuan of Series A financing was completed. This round of financing was led by Qianhai Fund of Funds, and the old shareholders Shanghai Biomedical Fund and Yuansheng Venture Capital also participated in the investment. Xingyuan Zhitong continued to act as the exclusive financial advisor.
This article is reproduced from: https://www.itjuzi.com/investevent/13231801
This site is for inclusion only, and the copyright belongs to the original author.